Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.

Name: Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.
Published: 2013
License: Public Domain

Fondazione Italiana Linfomi - ETS · 2013

ClinicalTrials.gov · Datasets · License: Public Domain · 2013

Open Source ↗

diffuse large b-cell lymphoma refractory, diffuse large b-cell lymphoma recurrent, diffuse large b-cell lymphoma (dlbcl), bortezomib, interventional, phase2, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.

Related documents